1. Kaul S, Diamond GA. Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 2010; 55: 415–427.
2. Lang T, Secic M. How to Report Statistics in Medicine: Annotated Guidelines for Authors, Editors, and Reviewers. 2nd ed. Philadelphia, PA, American College of Physicians, 2006.
3. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887.
4. Lee JJ. Demystify statistical significance—time to move on from the P value to Bayesian analysis. J Natl Cancer Inst 2011; 103: 2–3.
5. Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst 2011; 103: 16–20.
6. Sackett DL. Superiority, equivalence, and noninferiority trials, in Haynes B, Sackett DL, Guyatt G, et al. (eds): Clinical Epidemiology: How to Do Clinical Practice Research. 3rd ed. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 193–196.
7. Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc 2009; 57: 536–546.
8. van Wijk RG. From statistical significance to clinical relevance. Clin Exp Allergy 2010; 40: 197–199.
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.
10. Zarich SW. Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol 2009; 5: 500–506.
11. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009; 119: 2051–2057.
12. Stone GW, Pocock SJ. Randomized trials, statistics, and clinical inference. J Am Coll Cardiol 2010; 55: 428–431.
13. Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 348–352.
14. Kip KE, Hollabaugh K, Marroquin OC, et al. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008; 51: 701–707.
15. Mansi I, Reddy P, Carden D. Caveats and controversies in interpretation of cardiac troponins. Johns Hopkins Adv Stud Med 2005; 5: 428–435.
16. Kaul S, Diamond GA. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog Cardiovasc Dis 2007; 49: 284–299.
17. Mattos LA, Grines CL, Sousa JE, et al. One-year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients. A substudy of the STENT PAMI trial. Arq Bras Cardiol 2001; 77: 549–561.
18. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.
19. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93–98.
20. Pocock SJ, Ware JH. Translating statistical findings into plain English. Lancet 2009; 373: 1926–1928.
21. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189–2194.
22. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006; 145: 62–69.
23. DeMaria AN. Lies, damned lies, and statistics. J Am Coll Cardiol 2008; 52: 1430–1431.
24. Montori V, Ioannidis J, Jaeschke R, et al. Dealing with misleading presentations of clinical trial results, in Guyatt G, Rennie D, Meade M, et al. (eds): User’s Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 2nd ed. Chicago, IL, American Medical Association, 2008, pp 301–315.
25. Counsell CE, Clarke MJ, Slattery J, et al. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? BMJ 1994; 309: 1677–1681.
26. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci 1993; 703: 314–340.
27. Greenhalgh T. How to read a paper. Papers that report drug trials. BMJ 1997; 315: 480–483.
28. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878–2886.
29. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162–172.
30. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 2004; 38: 579–585.
31. Fleming TR. Clinical trials: discerning hype from substance. Ann Intern Med 2010; 153: 400–406.
32. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184–1190.
33. Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43–51.
34. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125–133.
35. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222–228.
36. Glasser SP, Howard G. Clinical trial design issues: at least 10 things you should look for in clinical trials. J Clin Pharmacol 2006; 46: 1106–1115.
37. Psaty BM. Conflict of interest, disclosure, and trial reports. JAMA 2009; 301: 1477–1479.
38. Bassler D, Ferreira-Gonzalez I, Briel M, et al. Systematic reviewers neglect bias that results from trials stopped early for benefit. J Clin Epidemiol 2007; 60: 869–873.
39. Fleming TR. Identifying and addressing safety signals in clinical trials. N Engl J Med 2008; 359: 1400–1402.
40. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419–430.
41. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–2207.
42. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010; 170: 1032–1036.
43. McAlister FA, Straus SE, Guyatt GH, et al. Users’ guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based View Full Text